Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease

Vicki J. Hwang, Xia Zhou, Xiaonan Chen, Josephine Trott, Omran Abuaboud, Kyuhwan Shim, Lai Kuan Dionne, Kenneth J. Chmiel, William Senapedis, Erkan Baloglu, Moe R. Mahjoub, Xiaogang Li, Robert H Weiss

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a common hereditary renal disease with no currently available targeted therapies. Based on the established connection between β-catenin signaling and renal ciliopathies, and on data from our and other laboratories showing striking similarities of this disease and cancer, we evaluated the use of an orally bioavailable small molecule, KPT-9274 (a dual inhibitor of the protein kinase PAK4 and nicotinamide phosphoribosyl transferase), for treatment of ADPKD. Treatment of PKD-derived cells with this compound not only reduces PAK4 steady-state protein levels and regulates β-catenin signaling, but also inhibits nicotinamide phosphoribosyl transferase, the rate-limiting enzyme in a key NAD salvage pathway. KPT-9274 can attenuate cellular proliferation and induce apoptosis associated with a decrease in active (phosphorylated) PAK4 and β-catenin in several Pkd1-null murine cell lines, with a less pronounced effect on the corresponding phenotypically normal cells. Additionally, KPT-9274 shows inhibition of cystogenesis in an ex vivo model of cyclic AMP-induced cystogenesis as well as in the early stage Pkd1 flox/flox :Pkhd1-Cre mouse model, the latter showing confirmation of specific anti-proliferative, apoptotic, and on-target effects. NAD biosynthetic attenuation by KPT-9274, while critical for highly proliferative cancer cells, does not appear to be important in the slower growing cystic epithelial cells during cystogenesis. KPT-9274 was not toxic in our ADPKD animal model or in other cancer models. Thus, this small molecule inhibitor could be evaluated in a clinical trial as a viable therapy of ADPKD.

Original languageEnglish (US)
JournalKidney International
DOIs
StateAccepted/In press - Jul 26 2016

Fingerprint

Autosomal Dominant Polycystic Kidney
Catenins
Niacinamide
Transferases
NAD
Kidney
Null Lymphocytes
Neoplasms
Inborn Genetic Diseases
Poisons
Protein Kinase Inhibitors
Cyclic AMP
Animal Models
Epithelial Cells
Cell Proliferation
Clinical Trials
Apoptosis
Cell Line
Enzymes
Therapeutics

Keywords

  • ADPKD
  • Apoptosis
  • Signaling

ASJC Scopus subject areas

  • Medicine(all)
  • Nephrology

Cite this

Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease. / Hwang, Vicki J.; Zhou, Xia; Chen, Xiaonan; Trott, Josephine; Abuaboud, Omran; Shim, Kyuhwan; Dionne, Lai Kuan; Chmiel, Kenneth J.; Senapedis, William; Baloglu, Erkan; Mahjoub, Moe R.; Li, Xiaogang; Weiss, Robert H.

In: Kidney International, 26.07.2016.

Research output: Contribution to journalArticle

Hwang, Vicki J. ; Zhou, Xia ; Chen, Xiaonan ; Trott, Josephine ; Abuaboud, Omran ; Shim, Kyuhwan ; Dionne, Lai Kuan ; Chmiel, Kenneth J. ; Senapedis, William ; Baloglu, Erkan ; Mahjoub, Moe R. ; Li, Xiaogang ; Weiss, Robert H. / Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease. In: Kidney International. 2016.
@article{0dd6ce2b93a849fea671a7a4c68281b4,
title = "Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease",
abstract = "Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a common hereditary renal disease with no currently available targeted therapies. Based on the established connection between β-catenin signaling and renal ciliopathies, and on data from our and other laboratories showing striking similarities of this disease and cancer, we evaluated the use of an orally bioavailable small molecule, KPT-9274 (a dual inhibitor of the protein kinase PAK4 and nicotinamide phosphoribosyl transferase), for treatment of ADPKD. Treatment of PKD-derived cells with this compound not only reduces PAK4 steady-state protein levels and regulates β-catenin signaling, but also inhibits nicotinamide phosphoribosyl transferase, the rate-limiting enzyme in a key NAD salvage pathway. KPT-9274 can attenuate cellular proliferation and induce apoptosis associated with a decrease in active (phosphorylated) PAK4 and β-catenin in several Pkd1-null murine cell lines, with a less pronounced effect on the corresponding phenotypically normal cells. Additionally, KPT-9274 shows inhibition of cystogenesis in an ex vivo model of cyclic AMP-induced cystogenesis as well as in the early stage Pkd1 flox/flox :Pkhd1-Cre mouse model, the latter showing confirmation of specific anti-proliferative, apoptotic, and on-target effects. NAD biosynthetic attenuation by KPT-9274, while critical for highly proliferative cancer cells, does not appear to be important in the slower growing cystic epithelial cells during cystogenesis. KPT-9274 was not toxic in our ADPKD animal model or in other cancer models. Thus, this small molecule inhibitor could be evaluated in a clinical trial as a viable therapy of ADPKD.",
keywords = "ADPKD, Apoptosis, Signaling",
author = "Hwang, {Vicki J.} and Xia Zhou and Xiaonan Chen and Josephine Trott and Omran Abuaboud and Kyuhwan Shim and Dionne, {Lai Kuan} and Chmiel, {Kenneth J.} and William Senapedis and Erkan Baloglu and Mahjoub, {Moe R.} and Xiaogang Li and Weiss, {Robert H}",
year = "2016",
month = "7",
day = "26",
doi = "10.1016/j.kint.2017.03.031",
language = "English (US)",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease

AU - Hwang, Vicki J.

AU - Zhou, Xia

AU - Chen, Xiaonan

AU - Trott, Josephine

AU - Abuaboud, Omran

AU - Shim, Kyuhwan

AU - Dionne, Lai Kuan

AU - Chmiel, Kenneth J.

AU - Senapedis, William

AU - Baloglu, Erkan

AU - Mahjoub, Moe R.

AU - Li, Xiaogang

AU - Weiss, Robert H

PY - 2016/7/26

Y1 - 2016/7/26

N2 - Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a common hereditary renal disease with no currently available targeted therapies. Based on the established connection between β-catenin signaling and renal ciliopathies, and on data from our and other laboratories showing striking similarities of this disease and cancer, we evaluated the use of an orally bioavailable small molecule, KPT-9274 (a dual inhibitor of the protein kinase PAK4 and nicotinamide phosphoribosyl transferase), for treatment of ADPKD. Treatment of PKD-derived cells with this compound not only reduces PAK4 steady-state protein levels and regulates β-catenin signaling, but also inhibits nicotinamide phosphoribosyl transferase, the rate-limiting enzyme in a key NAD salvage pathway. KPT-9274 can attenuate cellular proliferation and induce apoptosis associated with a decrease in active (phosphorylated) PAK4 and β-catenin in several Pkd1-null murine cell lines, with a less pronounced effect on the corresponding phenotypically normal cells. Additionally, KPT-9274 shows inhibition of cystogenesis in an ex vivo model of cyclic AMP-induced cystogenesis as well as in the early stage Pkd1 flox/flox :Pkhd1-Cre mouse model, the latter showing confirmation of specific anti-proliferative, apoptotic, and on-target effects. NAD biosynthetic attenuation by KPT-9274, while critical for highly proliferative cancer cells, does not appear to be important in the slower growing cystic epithelial cells during cystogenesis. KPT-9274 was not toxic in our ADPKD animal model or in other cancer models. Thus, this small molecule inhibitor could be evaluated in a clinical trial as a viable therapy of ADPKD.

AB - Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a common hereditary renal disease with no currently available targeted therapies. Based on the established connection between β-catenin signaling and renal ciliopathies, and on data from our and other laboratories showing striking similarities of this disease and cancer, we evaluated the use of an orally bioavailable small molecule, KPT-9274 (a dual inhibitor of the protein kinase PAK4 and nicotinamide phosphoribosyl transferase), for treatment of ADPKD. Treatment of PKD-derived cells with this compound not only reduces PAK4 steady-state protein levels and regulates β-catenin signaling, but also inhibits nicotinamide phosphoribosyl transferase, the rate-limiting enzyme in a key NAD salvage pathway. KPT-9274 can attenuate cellular proliferation and induce apoptosis associated with a decrease in active (phosphorylated) PAK4 and β-catenin in several Pkd1-null murine cell lines, with a less pronounced effect on the corresponding phenotypically normal cells. Additionally, KPT-9274 shows inhibition of cystogenesis in an ex vivo model of cyclic AMP-induced cystogenesis as well as in the early stage Pkd1 flox/flox :Pkhd1-Cre mouse model, the latter showing confirmation of specific anti-proliferative, apoptotic, and on-target effects. NAD biosynthetic attenuation by KPT-9274, while critical for highly proliferative cancer cells, does not appear to be important in the slower growing cystic epithelial cells during cystogenesis. KPT-9274 was not toxic in our ADPKD animal model or in other cancer models. Thus, this small molecule inhibitor could be evaluated in a clinical trial as a viable therapy of ADPKD.

KW - ADPKD

KW - Apoptosis

KW - Signaling

UR - http://www.scopus.com/inward/record.url?scp=85019594346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019594346&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2017.03.031

DO - 10.1016/j.kint.2017.03.031

M3 - Article

JO - Kidney International

JF - Kidney International

SN - 0085-2538

ER -